

| | | | |
|---|--|--|-------------------------------|
| FORM PTO-1449 (REV. 7-80) | U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE | ATTY. DOCKET NO. 720109.404 | APPLICATION NO. 10/698,955 |
| INFORMATION DISCLOSURE STATEMENT (use several sheets if necessary) | | APPLICANTS Edward S. Neuvelt et al. | |
| | | FILING DATE October 31, 2003 | GROUP ART UNIT 1616 |

U.S. PATENT DOCUMENTS

| *EXAMINER INITIAL | DOCUMENT NUMBER | DATE | NAME | CLASS | SUBCLASS | FILING DATE IF APPROPRIATE |
|-------------------|-----------------|----------|-----------------|-------|----------|----------------------------|
| JL | AA 5,906,984 | 05/25/99 | Capizzi et al. | 514 | 114 | |
| JL | AB 5,994,409 | 11/30/99 | Stogniew et al. | 514 | 665 | |
| EL | AC 6,573,253 | 06/03/03 | Stogniew | 514 | 114 | |
| JL | AD 2003/0157191 | 08/21/03 | Kil et al. | 424 | 649 | |

FOREIGN PATENT DOCUMENTS



| | DOCUMENT NUMBER | DATE | COUNTRY | TRANSLATION | |
|----|-----------------|----------|---------|-------------|----|
| | | | | YES | NO |
| JL | AE EP 624377 B1 | 01/23/02 | EPO | | |
| | AF WO 92/08448 | 05/29/92 | WIPO | | |
| | AG WO 94/00141 | 01/06/94 | WIPO | | |
| | AH WO 94/03179 | 02/17/94 | WIPO | | |
| | AI WO 96/14852 | 05/23/96 | WIPO | | |
| | AJ WO 96/26643 | 09/06/96 | WIPO | | |
| | AK WO 98/11898 | 03/26/98 | WIPO | | |
| | AL WO 98/34622 | 08/13/98 | WIPO | | |
| | AM WO 99/29312 | 06/17/99 | WIPO | | |
| | AN WO 01/80832 | 11/01/01 | WIPO | | |
| SL | AO WO 02/17962 | 03/07/02 | WIPO | | |

OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)

| | | |
|----|----|---|
| JL | AP | Alvarado, C.S. et al., "Chemotherapy for Patients with Recurrent or Refractory Neuroblastoma: A POG Phase II Study," <i>Journal of Pediatric Hematology/Oncology</i> 19(1): 62-67, February 1997. |
| SL | AQ | Blakley, B.W. et al., "Strategies for Prevention of Toxicity Caused by Platinum-Based Chemotherapy: Review and Summary of the Annual Meeting of the Blood-Brain Barrier Disruption Program, Gleneden Beach, Oregon, March 10, 2001," <i>The Laryngoscope</i> 112(11): 1997-2001, November 2002. |

| EXAMINER | DATE CONSIDERED |
|----------|-----------------|
| JL | 12/9/2003 |

* EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant(s).

| | | | | | | | |
|---|--|------|---------|--|------------------------|--------------------------------|-------------------------------|
| FORM PTO-1449 (REV.7-80) | | | | U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE | | ATTY. DOCKET NO. 720109.404 | APPLICATION NO. 10/698,955 |
| INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary) | | | | APPLICANTS Edward S. Neuwelt et al. | | | |
| | | | | FILING DATE October 31, 2003 | GROUP ART UNIT 1616 | | |
| U.S. PATENT DOCUMENTS | | | | | | | |
| EXAMINER INITIAL BA | DOCUMENT NUMBER | DATE | NAME | CLASS | SUBCLASS | FILING DATE IF APPROPRIATE | |
| FOREIGN PATENT DOCUMENTS | | | | | | | |
| | DOCUMENT NUMBER | DATE | COUNTRY | | | TRANSLATION YES NO | |
| | BB | | | | | | |
| OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.) | | | | | | | |
|  BC | Blay, J.Y. et al., "A Risk Model for Thrombocytopenia Requiring Platelet Transfusion After Cytotoxic Chemotherapy," <i>Blood</i> 92(2): 405-410, July 15, 1998. | | | | | | |
|  BD | Budd, G.T. et al., "Clinical Effects of Amifostine (Ethylol [®]) in Patients Treated with Carboplatin," <i>European Journal of Cancer</i> 32A(Suppl. 4): S43-S45, October 1996. | | | | | | |
|  BE | Butterworth, M. et al., "Cysteine Isopropylester Protects Against Paracetamol-Induced Toxicity," <i>Biochemical Pharmacology</i> 43(3): 483-488, 1992. | | | | | | |
|  BF | Case, B.C. et al., "The Pharmacokinetics and Pharmacodynamics of GW395058, a Peptide Agonist of the Thrombopoietin Receptor, in the Dog, a Large-Animal Model of Chemotherapy-Induced Thrombocytopenia," <i>Stem Cells</i> 18: 360-365, 2000. | | | | | | |
|  BG | Dahlborg, S.A. et al., "The Potential for Complete and Durable Response in Nonglial Primary Brain Tumors in Children and Young Adults with Enhanced Chemotherapy Delivery," <i>The Cancer Journal from Scientific American</i> 4(2): 110-124, March/April 1998. | | | | | | |
|  BH | Database BIOSIS, STN/CAS Online, Accession No. 2002:129589, Doolittle et al., <i>Blood</i> 98(11, Part 1): 37a-38a, November 2001. | | | | | | |
|  BI | de Jong, R.S. et al., "Phase II Study of Intraperitoneal Cisplatin Plus Systemic Etoposide as Second-line Treatment in Patients With Small Volume Residual Ovarian Cancer," <i>European Journal of Cancer</i> 31A(5): 709-713, 1995. | | | | | | |
|  BJ | Doolittle, N.D. et al., "Delayed Sodium Thiosulfate as an Otoprotectant Against Carboplatin-induced Hearing Loss in Patients with Malignant Brain Tumors," <i>Clinical Cancer Research</i> 7: 493-500, March 2001. | | | | | | |
|  BK | Einhorn and Loehrer, "Ifosfamide chemotherapy for pancreatic carcinoma," <i>Cancer Chemotherapy and Pharmacology</i> 18(Suppl. 2): S51-S54, 1986. | | | | | | |
|  BL | Harker, L.A. et al., "Prevention of Thrombocytopenia and Neutropenia in a Nonhuman Primate Model of Marrow Suppressive Chemotherapy by Combining Pegylated Recombinant Human Megakaryocyte Growth and Development Factor and Recombinant Human Granulocyte Colony-Stimulating Factor," <i>Blood</i> 89(1): 155-165, January 1, 1997. | | | | | | |
| EXAMINER  | | | | DATE CONSIDERED  | | | |
| * EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant(s). | | | | | | | |

| | | | | | |
|---|--|--|--|--------------------------------|-------------------------------|
| FORM PTO-1449 (REV.7-80) | | U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE | | ATTY. DOCKET NO. 720109.404 | APPLICATION NO. 10/698,955 |
| INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary) | | APPLICANTS Edward S. Neuwelt et al. | | | |
| | | FILING DATE October 31, 2003 | | GROUP ART UNIT 1616 | |

U.S. PATENT DOCUMENTS

| *EXAMINER INITIAL | | DOCUMENT NUMBER | DATE | NAME | CLASS | SUBCLASS | FILING DATE IF APPROPRIATE |
|-------------------|----|-----------------|------|------|-------|----------|----------------------------|
| | CA | | | | | | |


FOREIGN PATENT DOCUMENTS

| | | DOCUMENT NUMBER | DATE | COUNTRY | TRANSLATION YES NO |
|--|----|-----------------|------|---------|-----------------------|
| | CB | | | | |

OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)

| | | |
|-----------|----|---|
| <i>JL</i> | CC | Howell, S.B. et al., "Intraperitoneal Cisplatin with Systemic Thiosulfate Protection," <i>Annals of Internal Medicine</i> 97(6): 845-851, December 1982. |
| | CD | Isaacs, C. et al., "Randomized Placebo-Controlled Study of Recombinant Human Interleukin-11 to Prevent Chemotherapy-Induced Thrombocytopenia in Patients With Breast Cancer Receiving Dose-Intensive Cyclophosphamide and Doxorubicin," <i>Journal of Clinical Oncology</i> 15(11): 3368-3377, November 1997. |
| | CE | Iwamoto, Y. et al., "Two-Route Chemotherapy' Using High-Dose Ip Cisplatin and Iv Sodium Thiosulfate, Its Antidote, for Peritoneally Disseminated Cancer in Mice," <i>Cancer Treatment Reports</i> 68(11): 1367-1373, November 1984. |
| | CF | Kim, S. et al., "Dose intensification of cisplatin chemotherapy through biweekly administration," <i>Annals of Oncology</i> 4: 221-227, 1993. |
| | CG | Muldoon, L.L. et al., "Delayed Administration of Sodium Thiosulfate in Animal Models Reduces Platinum Ototoxicity without Reduction of Antitumor Activity," <i>Clinical Cancer Research</i> 6: 309-315, January 2000. |
| | CH | Muldoon, L.L. et al., "Rescue from Enhanced Alkylator-Induced Cell Death with Low Molecular Weight Sulfur-Containing Chemoprotectants," <i>The Journal of Pharmacology and Experimental Therapeutics</i> 296(3): 797-805, 2001. |
| | CI | Neuwelt, E.A. et al., "First Evidence of Otoprotection Against Carboplatin-Induced Hearing Loss with a Two-Compartment System in Patients with Central Nervous System Malignancy Using Sodium Thiosulfate," <i>The Journal of Pharmacology and Experimental Therapeutics</i> 286(1): 77-84, 1998. |
| | CJ | Neuwelt, E.A. et al., "In Vitro and Animal Studies of Sodium Thiosulfate as a Potential Chemoprotectant against Carboplatin-induced Ototoxicity," <i>Cancer Research</i> 56(4): 706-709, February 15, 1996. |
| <i>JL</i> | CK | Neuwelt, E.A. et al., "Therapeutic Efficacy or Aortic Administration of N-Acetylcysteine as a Chemoprotectant against Bone Marrow Toxicity after Intracarotid Administration of Alkylators, with or without Glutathione Depletion in a Rat Model," <i>Cancer Research</i> 61: 7868-7874, November 1, 2001. |

| EXAMINER | DATE CONSIDERED |
|---|-----------------|
| <i>JL</i> | 12/9/2005 |
| * EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant(s). | |

| | | | | | | | |
|---|----|-----------------|---|--|------------------------|--------------------------------|-------------------------------|
| FORM PTO-1449 (REV.7-80) | | | | U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE | | ATTY. DOCKET NO. 720109.404 | APPLICATION NO. 10/698,955 |
| INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary) | | | | APPLICANTS Edward S. Neuwelt et al. | | | |
| | | | | FILING DATE October 31, 2003 | GROUP ART UNIT 1616 | | |
| U.S. PATENT DOCUMENTS | | | | | | | |
| *EXAMINER INITIAL | | DOCUMENT NUMBER | DATE | NAME | CLASS | SUBCLASS | FILING DATE IF APPROPRIATE |
| | DA | | | | | | |
| FOREIGN PATENT DOCUMENTS | | | | | | | |
| | | DOCUMENT NUMBER | DATE | COUNTRY | | | TRANSLATION YES NO |
| | DB | | | | | | |
| OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.) | | | | | | | |
| JP | DC | | Piperno, E. et al., "Pathophysiology of Acetaminophen Overdosage Toxicity: Implication for Management," <i>Pediatrics</i> 62(5 - Supplement): 880-889, November 1978. | | | | |
| | DD | | Robbins, K.T. et al., "Efficacy of Targeted Supradose Cisplatin and Concomitant Radiation Therapy for Advanced Head and Neck Cancer: The Memphis Experience," <i>International Journal of Radiation Oncology Biology Physics</i> 38(2): 263-271, May 1, 1997. | | | | |
| | DE | | Trail, P.A. et al., "Enhanced Antitumor Activity of Paclitaxel in Combination with the Anticarcinoma Immunoconjugate BR96-Doxorubicin," <i>Clinical Cancer Research</i> 5: 3632-3638, November 1999. | | | | |
| | DF | | Vermeulen, N.P.E. et al., "Toxicity of fotemustine in rat hepatocytes and mechanism-based protection against it," <i>Chemico-Biological Interactions</i> 110: 139-158, 1998. | | | | |
| | DG | | Verschraagen, M. et al., "Pharmacokinetics and preliminary clinical data of the novel chemoprotectant BNP7787 and cisplatin and their metabolites," <i>Clinical Pharmacology & Therapeutics</i> 74(2): 157-169, August 2003. | | | | |
| PR | DH | | Wheeler, B.M. et al., "Ifosfamide in Refractory Male Germ Cell Tumors," <i>Journal of Clinical Oncology</i> 4(1): 28-34, January 1986. | | | | |
| | DI | | | | | | |
| | DJ | | | | | | |
| | DK | | | | | | |
| | DL | | | | | | |
| EXAMINER  | | | DATE CONSIDERED 12/9/2005 | | | | |
| * EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant(s). | | | | | | | |